• Pyxis Oncology reported a 36% confirmed response rate for MICVO monotherapy in 33 evaluable patients with previously treated recurrent or metastatic head-and-neck cancer.
• Median progression-free survival reached 6.2 months; estimated 12-month overall survival was 79% in the dose-capped subgroup.
• Grade 3 or higher treatment-related adverse events affected 54.3% of 35 patients; no treatment-related deaths occurred.
• Updated first-line pembrolizumab combination data are expected in December 2026; monotherapy overall survival data are due in the first half of 2027.
• A strengthened balance sheet supports advancement toward the planned Headliner Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.